Abiraterone acetate for prostate cancer: a new era of hormonal therapies.
作者信息
Antonarakis Emmanuel S
机构信息
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.
出版信息
Asian J Androl. 2011 Sep;13(5):663-4. doi: 10.1038/aja.2011.92. Epub 2011 Jul 11.
Abstract
摘要
相似文献
1
Abiraterone acetate for prostate cancer: a new era of hormonal therapies.醋酸阿比特龙用于前列腺癌：激素疗法的新时代。
Asian J Androl. 2011 Sep;13(5):663-4. doi: 10.1038/aja.2011.92. Epub 2011 Jul 11.
2
Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials.循环肿瘤细胞作为去势抵抗性前列腺癌试验中的替代生物标志物。
Eur Urol. 2011 Nov;60(5):905-7. doi: 10.1016/j.eururo.2011.08.024. Epub 2011 Aug 19.
3
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].[醋酸阿比特龙（AA）：阿比特龙的当前处方指南]
Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932.
4
Abiraterone acetate.醋酸阿比特龙。
Drugs R D. 2010;10(4):261-9. doi: 10.2165/11587960-000000000-00000.
5
[Management of enzalutamide, a new hormonal therapy].[新型激素疗法恩杂鲁胺的管理]
Bull Cancer. 2014 Jan 1;101(1):107-12. doi: 10.1684/bdc.2013.1880.
6
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.醋酸阿比特龙在化疗初治的转移性去势抵抗性前列腺癌中显示出与血清学反应不一致的骨闪烁现象的 II 期研究。
Clin Cancer Res. 2011 Jul 15;17(14):4854-61. doi: 10.1158/1078-0432.CCR-11-0815. Epub 2011 Jun 1.
7
Abiraterone in metastatic prostate cancer without previous chemotherapy.阿比特龙治疗既往未接受化疗的转移性前列腺癌。
N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10.
8
Abiraterone acetate for metastatic prostate cancer.醋酸阿比特龙用于转移性前列腺癌
Lancet Oncol. 2012 Oct;13(10):958-9. doi: 10.1016/S1470-2045(12)70392-3. Epub 2012 Sep 18.
9
Landmarks in hormonal therapy for prostate cancer.前列腺癌的激素治疗里程碑。
BJU Int. 2012 Oct;110 Suppl 1:23-9. doi: 10.1111/j.1464-410X.2012.11431.x.
10
[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].[前列腺癌与新的激素治疗：作用机制及主要临床结果]
Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7.
引用本文的文献
1
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.将进化动态纳入转移性去势抵抗性前列腺癌的治疗中。
Nat Commun. 2017 Nov 28;8(1):1816. doi: 10.1038/s41467-017-01968-5.
本文引用的文献
1
Expanding treatment options for metastatic prostate cancer.扩大转移性前列腺癌的治疗选择。
N Engl J Med. 2011 May 26;364(21):2055-8. doi: 10.1056/NEJMe1102758.
2
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
3
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.不断变化的多西他赛耐药性去势抵抗性前列腺癌的治疗标准。
Prostate Cancer Prostatic Dis. 2011 Sep;14(3):192-205. doi: 10.1038/pcan.2011.23. Epub 2011 May 17.
4
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌治疗方法的新进展。
Prostate Cancer Prostatic Dis. 2011 Sep;14(3):206-18. doi: 10.1038/pcan.2011.24. Epub 2011 May 17.
5
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.转移性前列腺癌的新策略：靶向雄激素受体信号通路。
Clin Cancer Res. 2011 Apr 1;17(7):1649-57. doi: 10.1158/1078-0432.CCR-10-0567. Epub 2011 Mar 3.
6
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.地舒单抗对比唑来膦酸治疗去势抵抗性前列腺癌骨转移患者的随机、双盲研究。
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
7
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
8
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
9
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.醋酸阿比特龙的 CYP17 抑制剂的 I 期临床试验表明，在接受过酮康唑治疗的去势抵抗性前列腺癌患者中具有临床活性。
J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16.
10
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.在基于紫杉烷的化疗后，酮康唑在去势抵抗性前列腺癌中的活性。
BJU Int. 2010 May;105(10):1392-6. doi: 10.1111/j.1464-410X.2009.08971.x. Epub 2009 Oct 23.
Zotero 插件